GlassScriptPhysician profile
Alyssa D Conjack
NPI 1598299661
$2,512.99
in general payments reported to CMS, 2019-2025
20 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $305 · 2021: $515 · 2022: $342 · 2023: $247 · 2024: $375 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $440.91 | 2019-2025 | Total30, Precision7, Precision 7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $343.19 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $290.90 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $266.10 | 2022-2025 | Infuse, Biotrue One Day, Vyzulta |
| Johnson & Johnson Vision Care, INC. | $225.05 | 2020-2025 | Acuvue |
| Eyevance Pharmaceuticals LLC | $170.30 | 2019-2022 | |
| Abb Con-Cise Optical Group LLC | $117.34 | 2019-2024 | Spectacle Lenses, Contact Lens |
| Oyster Point Pharma, INC. | $99.10 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $88.40 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $85.78 | 2019 | |
| Biotissue Holdings INC. | $70.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $63.97 | 2021-2023 | |
| Amgen INC. | $53.31 | 2024 | Tepezza |
| Allergan, INC. | $45.90 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $36.61 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $34.07 | 2024-2025 | Iyuzeh |
| Coopervision INC. | $31.08 | 2025 | Myday Contact Lens |
| Abbvie INC. | $21.76 | 2022 | |
| Visioneering Technologies, INC. | $15.44 | 2019 | |
| Dompe US, INC. | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Conjack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.